Infectious Disease News: September 20-27 Updates
“`html
recent Developments in Infectious Disease and Public health
Table of Contents
COVID-19 Vaccination Policy and Informed consent
recent clarification from Kevin ault, MD, regarding ACIP recommendations emphasizes that COVID-19 vaccination for individuals 6 months and older remains a matter of shared clinical decision-making. This highlights the importance of informed consent, though confusion exists around materials falling outside the ACIP’s direct purview. Dr. Ault also underscored the established standard of care for prenatal hepatitis B testing, despite ongoing implementation challenges.
ACIP continues to recommend separate MMR and varicella doses before age 4 to minimize the risk of febrile seizures. The long-standing practice of administering a hepatitis B birth dose remains supported by data demonstrating notable reductions in pediatric infections. Importantly, day-to-day clinical practice in obstetrics, pediatrics, and family medicine remains stable, with coverage expectations unchanged by major payers.
A New Approach to Antibiotic Development
Victor Nizet, MD, proposes a paradigm shift in antibiotic development, drawing parallels to cancer treatment. This approach emphasizes the integration of host immunity,recognizing that standard in vitro susceptibility tests may underestimate clinical activity by neglecting drug-immune synergy. Antibiotics can disrupt the protective microbiota and possibly carry long-term risks, making a holistic evaluation of the host-pathogen interaction essential.
Research from Dr.Nizet’s team, in collaboration with the University of Texas at Tyler, demonstrated that colistin retained activity against mcr-mediated resistant gram-negative bacteria under physiological conditions. Efficacy was observed in